Pharmaceutical News

RSS

Statins to carry revised warning labels: FDA

The U.S. FDA announced today that they would add additional safety warnings to the labels on statins, a class of drugs that lower cholesterol. Statins – with brand names Lipitor, Crestor and Zocor work by inhibiting the enzyme that plays a big part in the liver's production of cholesterol.

29 Feb 2012

Novartis defends challenge to Indian medicines patent law

Pharmaceutical company Novartis "has spoken out following criticism about its challenge to India's patent laws, insisting that access to life-saving drugs is not under peril by the move," Pharma Times World News reports. The case, which the Indian Supreme Court is scheduled to hear next month, challenges "Indian patent law, notably Section 3(d), which states that a modification of a known chemical composition is non-patentable," the news service writes.

29 Feb 2012

Combination treatment for pancreatic cancer increases intratumoral gemcitabine levels

Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer Discovery, a journal of the American Association for Cancer Research.

29 Feb 2012

Alzheimer's disease drugs may act like a bad electrician

Alzheimer's disease drugs now being tested in clinical trials may have potentially adverse side effects, according to new Northwestern Medicine research. A study with mice suggests the drugs could act like a bad electrician, causing neurons to be miswired and interfering with their ability to send messages to the brain.

29 Feb 2012

D-serine improves depressed rats' brain plasticity and memory

During depression, the brain becomes less plastic and adaptable, and thus less able to perform certain tasks, like storing memories. Researchers at the Swedish medical university Karolinska Institutet have now traced the brain's lower plasticity to reduced functionality in its support cells, and believe that learning more about these cells can pave the way for radical new therapies for depression.

29 Feb 2012

Activists protest Novartis challenge to Indian patent law

In this guest post in the Center for Global Health Policy's "Science Speaks" blog, Brook Baker of the Northeastern University School of Law Program on Human Rights and the Global Economy, "describes and comments on pharmaceutical company Novartis's court challenge to India's strict standards of patenting medicine" and worldwide protests against the company that took place last week prior to its shareholder meeting.

29 Feb 2012

HPV vaccine recommended for boys

The American Academy of Pediatrics has recommended boys - not just girls - be vaccinated against HPV, though questions about its cost-effectiveness remain.

29 Feb 2012

Shire, arGEN-X partner to create novel antibodies against rare diseases

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody platform, announces today that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire.

29 Feb 2012

SWHR, NAMS encourage women to understand benefits and risks of hormone therapy

Hormone therapy (HT) remains the most effective treatment available for menopausal hot flashes and night sweats. The Society for Women's Health Research (SWHR) and The North American Menopause Society (NAMS) encourage women to understand the benefits and risks of hormone therapy in order to decide if this therapy is right for them.

29 Feb 2012

First study to show effects of ecstasy drug on fetal and infant development

A study led by Case Western Reserve University School of Medicine, in collaboration with the University of East London UK, and Swansea University UK, is the first to show the effects of the drug ecstasy on fetal and infant development.

29 Feb 2012

Cannabinoids may be a target for new strategies in cancer treatment

Cannabis-like substances that are produced by the body have both therapeutic and harmful properties, besides their well-known intoxicating effects, and the body's cannabinoid system may be a target for new strategies in cancer treatment.

29 Feb 2012

Quitting hormone therapy can lead to breast tumor regression

As soon as women quit hormone therapy, their rates of new breast cancer decline, supporting the hypothesis that stopping hormones can lead to tumor regression, according to a report e-published in Cancer Epidemiology, Biomarkers, & Prevention.

29 Feb 2012

Maturitas publishes EMAS' clinical guide on SERMs against postmenopausal osteoporosis

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of an important clinical guide from the European Menopause and Andropause Society (EMAS) in the February issue of Maturitas.

29 Feb 2012

XL888 inhibitor can prevent vemurafenib resistance in melanoma patients

Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues in California have found that the XL888 inhibitor can prevent resistance to the chemotherapy drug vemurafenib, commonly used for treating patients with melanoma.

29 Feb 2012

Silver Hill Hospital announces opening of Chronic Pain and Addiction Center

Silver Hill Hospital, the nationally recognized psychiatric hospital in New Canaan, CT, announces the opening of the Chronic Pain and Addiction Center, an intensive residential treatment program for patients with pain who have become addicted to opioid medications.

28 Feb 2012

Biogen Idec receives FDA approval for two separate dosing innovations to treat MS

Today Biogen Idec announced that the U.S. Food and Drug Administration (FDA) has approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-a-week AVONEX for relapsing forms of multiple sclerosis (MS).

28 Feb 2012

FDA grants orphan drug designation to Ultragenyx UX003 for treatment of MPS 7

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for UX003 for the treatment of MPS 7.

28 Feb 2012

Blog examines sale of fake malaria drugs in Tanzania

In this post in Malaria Free Future's "Malaria Matters" blog, Bill Brieger, a professor in the health systems program of the Department of International Health at Johns Hopkins University, examines recent discoveries of fake malaria medications being sold in Tanzania.

28 Feb 2012

Telephone-based counseling program does not improve osteoporosis medication adherence

Telephone motivational counseling sessions did not result in a statistically significant improvement in adherence to an osteoporosis medication regimen, according to a report published Online First by Archives of Internal Medicine, one of the JAMA/Archives journals.

28 Feb 2012

Report identifies patterns in misuse of illicit and prescription drugs among young adults

A new report from researchers at the Drexel University School of Public Health identifies patterns in the misuse of illicit drugs among young adults who also misuse prescription drugs.

28 Feb 2012